Literature DB >> 9366624

Can we measure prior postmenopausal estrogen/progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial. The PEPI Investigators.

G A Greendale1, M K James, M A Espeland, E Barrett-Connor.   

Abstract

The objective of this study was to assess: 1) the accuracy of a single self-report question about postmenopausal estrogen use; and 2) the performance and repeated measures agreement of a standardized hormone use interview. Women (n = 863) in the Postmenopausal Estrogen/Progestin Interventions Trial (PEPI) completed a self-report baseline questionnaire (BQ) at enrollment and a History of Hormone Use interview (HHU) at the 3-month follow-up visit (HHU3mos). A subsample of 101 women completed a second HHU interview 3 years later (HHU3yrs). As determined by the HHU3mos, 479 (56%) of women had ever used postmenopausal estrogen and 261 (30%) had ever used postmenopausal progestin. The mean number of years since last estrogen or progestin use was 2.2 and 1.3 years, respectively. Overall, there was 95% agreement between self-reported estrogen use on the BQ and the HHU3mos (kappa = 0.91). Using the HHU3mos as the criterion standard, the BQ misclassified 2.3% of women as false positives and 6.3% as false negatives. The average duration of estrogen use in the false-negative classifications was 1.9 years (range: 1-9 years). On the HHU3mos, 39.7% of participants could not recall at least one of the specific details of estrogen use (preparation, dose, route, or starting or stopping year); similar patterns of recall were found for progestin use. Factors associated with discordant reporting of ever-use of ERT (BQ vs. HHU3mos) or incomplete reporting of estrogen/progestin use on the HHU3mos were: route of administration, recency of hormone use, duration of hormone use, and race. Age, years since menopause, education, income, and hysterectomy status were not related to discordant and/or incomplete reporting. Agreement between the HHU3mos and HHU3yrs for ever-use of estrogen was 85.2% (kappa = 0.71). In sum, a single self-report question was adequate to ascertain ever-use of postmenopausal estrogen. When a structured interview form was used, details of postmenopausal estrogen and progestin use were not well remembered. Some features of hormone use and participant characteristics were associated with completeness of recalled hormone use, which suggests the potential for differential misclassification.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366624     DOI: 10.1093/oxfordjournals.aje.a009352

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  9 in total

1.  Hysterectomy status, estrogen use and quality of life in older women: the Rancho Bernardo study.

Authors:  Donna Kritz-Silverstein; Denise G Von Muhlen; Theodore G Ganiats; Elizabeth Barrett-Connor
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

Review 2.  Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.

Authors:  Mark F Munsell; Brian L Sprague; Donald A Berry; Gary Chisholm; Amy Trentham-Dietz
Journal:  Epidemiol Rev       Date:  2014       Impact factor: 6.222

3.  The associations of hormone replacement therapy and preventive practices in minority women.

Authors:  Kalpana Ganesan; Senait Teklehaimanot; Merlyn Asuncion
Journal:  J Natl Med Assoc       Date:  2005-01       Impact factor: 1.798

4.  Cognitive benefits of hormone therapy: cardiovascular factors and healthy-user bias.

Authors:  Whitney Wharton; Maritza Dowling; Christine M Khosropour; Cynthia Carlsson; Sanjay Asthana; Carey E Gleason
Journal:  Maturitas       Date:  2009-10-29       Impact factor: 4.342

5.  Hormone replacement therapy and patterns of osteoarthritis: baseline data from the Ulm Osteoarthritis Study.

Authors:  A Erb; H Brenner; K P Günther; T Stürmer
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

6.  Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study.

Authors:  Sarah E Daugherty; James V Lacey; Ruth M Pfeiffer; Yikyung Park; Robert N Hoover; Debra T Silverman
Journal:  Int J Cancer       Date:  2013-02-12       Impact factor: 7.396

7.  Postoophorectomy estrogen use and breast cancer risk.

Authors:  Hazel B Nichols; Amy Trentham-Dietz; Polly A Newcomb; Linda J Titus; Kathleen M Egan; John M Hampton; Kala Visvanathan
Journal:  Obstet Gynecol       Date:  2012-07       Impact factor: 7.661

8.  Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.

Authors:  Ross L Prentice; Rowan T Chlebowski; Marcia L Stefanick; Joann E Manson; Mary Pettinger; Susan L Hendrix; F Allan Hubbell; Charles Kooperberg; Lewis H Kuller; Dorothy S Lane; Anne McTiernan; Mary Jo O'Sullivan; Jacques E Rossouw; Garnet L Anderson
Journal:  Am J Epidemiol       Date:  2008-03-27       Impact factor: 4.897

9.  Pre-diagnosis oophorectomy, estrogen therapy and mortality in a cohort of women diagnosed with breast cancer.

Authors:  Hazel B Nichols; Amy Trentham-Dietz; Polly A Newcomb; Kathleen M Egan; Linda J Titus; John M Hampton; Kala Visvanathan
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.